Recent breakthrough research published in the journal Small in April 2025 has unveiled a groundbreaking approach in cancer treatment. Scientists have developed a multifunctional nano-delivery system, TMBFG, by surface modifying MXene powder through a non-chemical modification strategy using bovine serum albumin (BSA). This innovative system combines MXene with manganese dioxide (MnO2) nanoparticles, folic acid (FA), and glucose oxidase (GOx) to target cancer cells, induce starvation, and achieve photothermal double killing effects.
The study demonstrated that when exposed to 808nm near-infrared light, the temperature of TMBFG solution increased with concentration. Even at low concentrations, temperatures could reach 49.5°C, while at a concentration of 0.8mg/mL, it could reach 57.8°C within 3 minutes, effectively killing cancer cells. TMBFG exhibited a photothermal conversion efficiency of 55.37%, showcasing excellent photothermal stability and reusability.
In vitro experiments showed that TMBFG exhibited significant targeting capability towards HeLa cells with high folate receptor (FR) expression, with fluorescence intensity being 1.6 times that of A549 cells. MTT assays indicated low toxicity of TMBFG towards normal and cancer cells, with potential to enhance cell proliferation at high concentrations, demonstrating good biocompatibility. In a mouse tumor model, the TMBFG+NIR group displayed significantly reduced tumor volumes with increased body weight, indicating a substantial inhibitory effect on tumor growth without adverse effects on normal mouse growth.
The development of the TMBFG nano-delivery system marks a significant advancement in cancer treatment. Through precise targeting and efficient delivery of therapeutic agents to cancer cells, coupled with photothermal therapy, this innovative approach demonstrates great promise for synergistic cancer therapy. The results of this study not only highlight the potential of MXene powder in cancer treatment but also underscore the importance of continuous research and innovation in the fight against cancer.
Literature name: Water‐Dispersible MXene Governs Glycolysis for Cancer Synergistic Therapy
